I know by talking with many of you and reading many of your insightful emails that the level of unease and mistrust is elevated—who to trust, what is important to know, and what is knowable have all become harder to discern. Lately, I have been hearing back from many newer members who wish they had a way of keeping tabs on all that goes on inside Fidelity—a sensibility I not only share, but aim to deliver each and every month. To bring this aspect of Fidelity Investor into sharper focus, this month's issue introduces a new-yet-old feature that gives you the inside scoop into what is going on at Fidelity. Read more
This week, I'm announcing a trade (effective June 2) in the Aggressive Growth and Growth portfolios that is designed provide our longer-term, more growth-oriented portfolios more complete exposure to undervalued foreign markets by increasing our exposure to emerging equities. In the U.S., the slow-growth road we’re on continues to pave the way for corporate profits; we’ve just seen the best quarterly performance for S&P 500 profits in over five years. At the same time, macro manufacturing and service sectors reports reflect a U.S. consumer in solid shape thanks to full employment and the confidence that corresponds with it. Read more
Inside this impactful FSI May issue, you'll find my investment views on whether this week's market dips herald the transition of the "Trump Rally" to a "Trump retreat." You’ll also find my Sector Focus on healthcare, a sector which experienced its own political malaise last year. My view: Greater global market demand, more innovation, and significantly better-managed businesses will continue to overcome any short-term political turmoil that seeks to upset investors' stomachs. To complement this month's healthcare Focus, I've interviewed one of the most intelligent biotechnology thinkers and investors you will ever come across, Rajiv Kaul, manager of Select Biotechnology. Rajiv has grown up right alongside the industry, and there’s no one I’ve met who can best his ability to keep this sector’s volatility in proper perspective. Finally, you'll find my Tactical Opportunity picks for near-term offense and defense, as well as my Inside Scoop section covering all the breaking Fidelity news that’s fit to print. Read more
Jim Lowell is Editor-in-Chief of the award-winning independent newsletters Fidelity Investor and Fidelity Sector Investor. Through his newsletters, Jim advises individual investors seeking superior performance from their Fidelity investments. He has also written several books on investing, Investing from Scratch (revised edition, Penguin, 2006) and What Every Fidelity Investor Needs to Know (Wiley, 2007) among them. Read more
|Growth & Income||6.6%||10.3%|
|Annuity Growth & Income||7.9%||8.1%|
You don't want to own too many funds that are similar, but how do you tell? A high correlation between funds may mean that your portfolio of funds is not as diverse as you might want it to be. While other tools may compare funds only to the S&P 500, you can use this tool to determine how closely the performance of one Fidelity fund tracks that of any other Fidelity fund. Compare all the funds that you own. To diversify, look for funds that have low correlation with one another.